Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Torokbalint – page 8

1 123 clinical trials in Torokbalint, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torokbalint at a glance
1 123
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 123 trials in Torokbalint

Open in trial search

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Neutropenia

Recruiting

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Efficacy and safety of zenagamtide versus semaglutide in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitors

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Torokbalint

What the registry says about research in the country

01 Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating innovative combination therapies and immunotherapy approaches.

  • Advanced NSCLC Treatments
  • Stage III-IV Cancer Therapies
  • Immunotherapy Combinations

Multiple studies investigating targeted therapies for various stages of lung cancer, particularly focusing on patients with specific genetic markers and PD-L1 expression levels.

02 Respiratory Conditions

Research initiatives addressing chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), testing new therapeutic approaches.

  • Uncontrolled Asthma Management
  • COPD Treatment Optimization
  • Cystic Fibrosis Therapies

Studies evaluating novel medications and combination therapies to improve patient outcomes in chronic respiratory conditions.

03 Innovative Therapeutics

Cutting-edge research examining novel drug combinations and treatment approaches, including targeted therapies and immunotherapy agents.

  • Combination Immunotherapies
  • Targeted Molecular Therapies
  • Maintenance Treatment Strategies

Focus on developing personalized treatment approaches based on specific biomarkers and genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.